Table 4.
Multivariable analysis of vision improvement for the PRN pattern and three-injections pattern
| Variables | PRN pattern | Three-injections pattern | ||||||
|---|---|---|---|---|---|---|---|---|
| Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | Crude OR (95% CI) | P-value | Adjusted OR (95% CI) | P-value | |
| Age | ||||||||
| >60 years | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | ||||
| 50 to 60 years | 1.18 (0.92-1.50) | 0.189 | 3.25 (1.86-5.67) | 0.000* | 1.87 (1.00-3.51) | 0.051 | 3.99 (1.48-10.76) | 0.006* |
| <50 years | 1.23 (0.95-1.58) | 0.113 | 2.92 (1.4-6.07) | 0.004* | 2.24 (1.10-4.56) | 0.027* | 18.38 (4.61-73.36) | 0.000* |
| Sex | ||||||||
| Male | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | ||||
| Female | 1.03 (0.84-1.26) | 0.788 | 0.8 (0.47-1.39) | 0.434 | 1.34 (0.80-2.27) | 0.271 | 1.20 (0.53-2.73) | 0.668 |
| Drug | ||||||||
| IVB | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | ||||
| IVR | 1.20 (0.68-2.12) | 0.691 | 1.18 (0.68-2.05) | 0.561 | 0.48 (0.20-1.17) | 0.109 | 0.86 (0.35-2.14) | 0.753 |
| Co-morbidity | ||||||||
| DM with other comorbidities | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | ||||
| DM without other comorbidities | 1.27 (0.90-1.80) | 0.179 | 1.02 (0.42-2.51) | 0.961 | 0.41 (0.11-1.61) | 0.202 | 0.16 (0.03-0.76) | 0.021* |
| non-DM with other comorbidities | 1.52 (1.15-2.01) | 0.003* | 0.91 (0.39-2.12) | 0.819 | 1.31 (0.70-2.43) | 0.400 | 0.83 (0.17-4.11) | 0.817 |
| non-DM without other comorbidities | 1.55 (1.16-20.7) | 0.003* | 1.52 (0.63-3.65) | 0.349 | 2.14 (1.06-4.32) | 0.034* | 0.70 (0.15-3.24) | 0.645 |
| Diagnosis | ||||||||
| Other diseases | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | 1.0 (reference) | ||||
| nAMD and PCV | 1.57 (1.06-2.32) | 0.023* | 1.66 (0.73-3.78) | 0.226 | 1.12 (0.48-2.63) | 0.787 | 2.36 (0.52-10.7) | 0.266 |
| DME | 1.32 (0.93-1.87) | 0.126 | 1.39 (0.49-3.97) | 0.535 | 1.21 (0.50-2.94) | 0.675 | 0.88 (0.15-5.13) | 0.883 |
| RVO | 3.66 (2.50-5.36) | 0.000* | 2.76 (1.20-6.34) | 0.017* | 2.26 (0.93-5.48) | 0.072 | 2.39 (0.66-8.62) | 0.182 |
| PDR | 1.25 (0.87-1.80) | 0.223 | 0.85 (0.30-2.41) | 0.756 | 0.88 (0.26-3.01) | 0.835 | 0.42 (0.04-4.09) | 0.454 |
| Baseline VAa | 1.05 (1.04-1.07) | 0.000* | 1.08 (1.04-1.13) | 0.000* | 1.08 (1.04-1.13) | 0.001* | 1.10 (1.02-1.18) | 0.009* |
| Number of drug injectionsa | 1.27 (1.06-1.54) | 0.012* | 1.43 (1.14-1.78) | 0.002* | - | - | - | - |
aContinuous variable
*P-value < 0.05
OR Odds Ratio, 95% CI 95% confidence interval, IVB intravitreal bevacizumab, IVR intravitreal ranibizumab, DM diabetes mellitus, nAMD Neovascular age-related macular degeneration, PCV polypoidal choroidal vasculopathy, DME Diabetic macular edema, RVO Retinal vein occlusion, PDR Proliferative diabetic retinopathy, VA Visual acuity